NICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a chemotherapy-free regimen with Roche’s MabThera. The cost-effectiveness agency ...

If you or your sexual partner can become pregnant, avoid pregnancy during the following time frames: while taking Revlimid when having treatment breaks for at least 4 weeks after your last dose It ...

Now, Revlimid is the first treatment to be made available for newly-diagnosed, post-transplant patients on the NHS, providing an alternative to the standard ‘watch-and-wait’ approach.

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.